How much cash does Evommune generate?

Evommune (EVMN) generated -$2.9M in operating cash flow over the trailing twelve months.

Where does Evommune 's cash flow data come from?

Every line is extracted from Evommune 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Evommune EVMN Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25
Net income	——
Depreciation and amortization	——
Stock-based compensation	——
Provision for credit losses	——
Change in accounts receivable	——
Change in inventories	——
Change in accounts payable	——
Change in other assets	——
Change in other liabilities	——
Other working capital changes	——
Amortization of intangible assets	——
Non-cash operating lease expense	——
Loss on extinguishment of debt	——
Change in operating lease liabilities	——
Distributions from equity method investments	——
Net cash from operating activities	——
Repurchases of common stock	$1.2M—
Proceeds from issuance of debt	$123.75K—
Repayments of debt	——
Proceeds from issuance of common stock	$543.07K—
Redemption of preferred stock	$180.33K—
Proceeds from issuance of preferred stock	$8M—
Net cash from financing activities	——
Net increase (decrease) in cash	——
Interest paid	——
Allowance For Inventory Obsolescence	——
Amortization of capitalized software and acquired intangible assets	——
Depreciation	——
Derivative Gain Loss On Derivative Net	$7.36M—
Change in fair value of the conversion option of the convertible senior notes	——
Financing Expense On Warrant Issuance	——
Gain (Loss) on Derivative Instruments, Net, Pretax	——
Gain (Loss) on Sale of Derivatives	-$7.36M—
Income Loss From Equity Method Investments Net Of Dividends Or Distributions	——
Operating lease liabilities	——
Current liabilities	——
Increase (Decrease) in Prepaid Expense and Other Assets	——
Issuance Of Common Stock For Convertible Debenture	$122.33K—
Issuance Of Shares For Note Extension	$80.5K—
Loss On Issuance Of Preferred Stock Derivative Liability	$5.29M—
Net income	——
Operating lease right-of-use asset amortization	——
Accounts Receivable, Credit Loss Expense (Reversal)	——
Gain (loss) on mark-to-market of Escrowed Shares	$7.36M—
Asset Acquisition, Consideration Transferred	——
Payments For Payable For Acquisition	——
Payments for Repurchase of Preferred Stock and Preference Stock	$180.33K—
Payments Of Stock Issuance Costs	——
Common stock issuance for private placement	——
Repayment Of Liability Conditional Timing	——
Repayments of Debt	——
Common Stock Convertible Conversion Price Decrease	$0.35—
Common Stock Convertible Conversion Price Increase	$0.41—
Exchange Offer (Note 12)	$115—
Cost of services	$3.13M—
Derivative Liability	$13.29M—
Earnings per common share - basic (in dollars per share)	——
Earnings per common share - diluted (in dollars per share)	——
General and administrative costs	$4.25M—
Gross Profit	$3.48M—
Interest Expense, Nonoperating	$402.4K—
Customer receivables and Other	$74.7K—
Operating Income Loss	-$1.4M—
Percentage Of Net Sales	——
Percentage Of Outstanding Principal Amount	——
Revenues	$6.61M—
Sales and marketing	$632.41K—
Weighted Average Number Of Diluted Share Outstanding	——
Diluted (in shares)	99.2M—
Weighted average common shares outstanding, basic (in shares)	——
Issuance of warrants	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Evommune .

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Evommune generate?: Evommune (EVMN) generated -$2.9M in operating cash flow over the trailing twelve months.
Where does Evommune 's cash flow data come from?: Every line is extracted from Evommune 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.